1.Isolation and identification of a new biotransformation compound by Fusarium sacchari from saponin of Panax notoginseng leaves
Dedong ZHANG ; Jiaqing CAO ; Yuqing ZHAO
Chinese Traditional and Herbal Drugs 1994;0(12):-
Objective To study the chemical constituents of transformed products by Fusarium sacchari and to find the rare ginsenosides with anti-tumor effects from the leaves of Panax notoginseng. Methods The compound isolated was separated by repeated silica gel,Sephadex LH-20,and HPLC chromatography. The structure was identified by analysis of its spectral data.Results A dammarane-type triterpene, notoginsenoside-LZ,20(S)-3?-hydroxy-12?,23-epoxy-dammar-24-ene-20-O-?-D-xylopyranosyl (1→6)-?-D-glucopyranoside,was isolated from the transformed products.Conclusion Notoginsenoside-LZ is a new compound.
2.Effectiveness and Safety of Recombinant Human Endostatin Combined with Concurrent Chemoradiotherapy for Advanced Non-small Cell Lung Cancer:a Meta-Analysis
Huilin XU ; Wei GE ; Dedong CAO ; Pingpo MING ; Yongfa ZHENG ; Jing SONG ; Wei LUO
Herald of Medicine 2014;(9):1237-1242
Objective To evaluate the effectiveness and safety of recombinant human endostatin combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for advanced non small cell lung cancer ( NSCLC) . Methods Electronic databases including the Cochrane library, PubMed, the Chinese biomedical literature database, China national knowledge internet(,EMbase,VIP and Wanfang database system were searched,until August,2013. The inclusion criteria was efficacy and safety studies of randomized controlled clinical studies in which recombinant human endostatin combined with concurrent chemoradiotherapy was compared with concurrent chemoradiotherapy alone for patients with advanced NSCLC. Cochrane handbook 5. 1. 0 was applied in evaluating the quality of included trials and RevMan 5. 1. 0 software was used for data analysis.Results Five studies including 217 cases of advanced NSCLC were included. The results of the meta-analysis exhibited that compared with concurrent chemoradiotherapy alone, recombinant human endostatin combined with concurrent chemoradiotherapy could increase effective rate [OR=2. 62,95%CI(1. 41,4. 86),P=0. 002]. But there were no significant differences in clinical benefit rate [OR=2. 08,95%CI(0. 92,4. 73),P=0. 08],one year survival rate [OR=1. 18,95%CI(0. 53,2. 66),P=0. 68], improvement in quality of life [OR=1. 57,95%CI(0. 40,6. 07),P=0. 52],rate of leucopenia [OR=1. 25,95%CI(0. 72,2. 17), P=0.43],radioactive esophagitis [OR=1. 16,95%CI(0. 42,3. 21),P=0. 77] and radiation pneumonitis [OR=2. 47,95%CI (0. 34,17. 68),P=0. 37]. Conclusion Compared with concurrent chemoradiotherapy alone,recombinant human endostatin combined with concurrent chemoradiotherapy may be more effective for advanced NSCLC,whereas improvement of life quality and toxicities are similar. For the quality restriction and possible publication bias of the included studies,more high quality randomized controlled trials are required to further verify this conclusion.
3. A survey on night sleep quality and daytime tiredness among shift nurses in a tertiary teaching hospital
Shujuan YU ; Yingjuan CAO ; Dedong MA
Chinese Journal of Industrial Hygiene and Occupational Diseases 2018;36(11):855-858
Objective:
To explore the night sleep quality of shift nurses and the current situation of their daytime tiredness, sleepiness, and to provide evidence for nursing administrators and managers to allocate human resources reasonably and prevent adverse events.
Methods:
The cross-sectional method was utilized to conduct a questionnaire survey among shift nurses in a tertiary teaching hospital in Shandong Province from March to May inclusive, 2017.
Results:
There was a total of 233 valid questionnaires returned. The prevalence of sleep disorder, daytime tiredness and sleepiness was 45.92%, 16.31% and 13.30%, respectively. The differences of the nurses' sleep quality at night between different ages, marriages, educational backgrounds and professional titles were statistically significant (